Walleye Capital
YMAB

Walleye Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Walleye Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27,393
Closed -$137K – 4952
2023
Q1 		$137K Sell
27,393
-11,207
-29% -$45.8K ﹤0.01% 2744
2022
Q4 		$188K Sell
38,600
-398,744
-91% -$2.9M ﹤0.01% 2080
2022
Q3 		$6.31M Buy
437,344
+21,204
+5% +$351K 0.12% 185
2022
Q2 		$6.3M Buy
+416,140
New +$4.86M 0.17% 134
2022
Q1 		– Sell
-17,188
Closed -$279K – 2639
2021
Q4 		$279K Buy
+17,188
New +$367K 0.01% 1293

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's YMAB Position: Q2 2023 in Review

Walleye Capital sold out of Y-mAbs Therapeutics (YMAB) in Q2 2023, closing a stake of 27,393 shares — an estimated $137K sold.

Walleye Capital first reported a position in YMAB in Q4 2021 and held it in 5 quarters. The position peaked at $6.31M in Q3 2022. 95 funds tracked by Wall St. Rank hold YMAB as of Q2 2023.

  • Walleye Capital reported no remaining Y-mAbs Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Capital sold 27,393 Y-mAbs Therapeutics shares in Q2 2023, an estimated $137K.
  • Walleye Capital first reported a position in Y-mAbs Therapeutics in Q4 2021 and held it in 5 quarters.
  • Walleye Capital's Y-mAbs Therapeutics position peaked at $6.31M in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.